Fluoroquinolone resistance in mycobacterium tuberculosis. What have we learnt?

International Journal of Tuberculosis and Lung Disease

Volumn 18, Issue 1, 2014, Pages 1-2

  Yew, Wing Wai ^a   Lange, Christoph ^b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b RESEARCH CENTER BORSTEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GATIFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BACTERIAL STRAIN; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG USE; EDITORIAL; GEOGRAPHY; HUMAN; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATIENT COMPLIANCE; PNEUMONIA; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; RELAPSE; SHORT COURSE THERAPY; TREATMENT DURATION; TUBERCULOSIS; DRUG EFFECTS; MICROBIOLOGY; MULTIDRUG RESISTANCE; RISK FACTOR; TREATMENT FAILURE; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTIBIOTICS, ANTITUBERCULAR; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FLUOROQUINOLONES; HUMANS; MYCOBACTERIUM TUBERCULOSIS; RISK FACTORS; TREATMENT FAILURE; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84892608835     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.13.0739     Document Type: Editorial

References (11)

1. Yew W W, Chan C K, Chau C H, et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofl oxacin/levofl oxacin-containing regimens. Chest 2000; 117:744-751
2. Huang T S, Kunin C M, Shin-Jung Lee S, Chen Y S, Tu H Z,Liu Y C. Trends in fl uoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese medical centre: 1995-2003. J Antimicrob Chemother 2005; 56: 1058-1062
3. Park I-N, Hong S-B, Oh Y-M, et al. Impact of short-term exposure to fl uoroquinolones on ofl oxacin resistance in HIV-negative patients with tuberculosis. Int J Tuberc Lung Dis 2007; 11: 319-324
4. Chen T C, Lu P L, Lin C Y, Lin W R, Chen Y H. Fluoroquinolones are associated with delayed treatment and resistance in tuberculosis: A systematic review and meta-analysis. Int J Infect Dis 2011; 15: e211-e216
5. Shen G H, Tsao T C, Kao S J, et al. Does empirical treatment of community-acquired pneumonia with fl uoroquinolones delay tuberculosis treatment and result in fl uoroquinolone resistance in Mycobacterium tuberculosis? Controversies and solutions. Int J Antimicrob Agents 2012; 39: 201-205
6. Long R, Chong H, Hoeppner V, et al. Empirical treatment of community-acquired pneumonia and the development of fl uoroquinolone-resistant tuberculosis. Clin Infect Dis 2009; 48: 1354-1360
7. Yew W-W, Nuermberger E. High-dose fl uoroquinolones in short-course regimens for treatment of MDR-TB: the way forward? Int J Tuberc Lung Dis 2013; 17: 853-854
8. Jawahar M S, Banurekha V V, Paramasivan C N, et al. Randomized clinical trial of thrice-weekly 4-month moxifl oxacin or gatifl oxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients. PLOS ONE 2013; 8: e67030
9. Chang K C, Leung C C, Grosset J, Yew W W. Treatment of tuberculosis and optimal dosing schedules. Thorax 2011; 66: 997-1007
10. Bate R, Jensen P, Hess K, Mooney L, Milligan J. Substandard and falsifi ed anti-tuberculosis drugs: A preliminary fi eld analysis. Int J Tuberc Lung Dis 2013; 17: 308-311
11. Chang K C, Yew W W. Management of diffi cult multidrugr esistant tuberculosis and extensively drug-resistant tuberculosis: update 2012. Respirology 2013; 18: 8-21